Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 18/20 | 0.53 |
| ▸ | TPO | P07202 | 16/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | PNP | P00491 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27223595 | 0.89 | MPO (0.51) | MPOTPOKCNH2CYP3A4MEN1 | |
| SCHEMBL30749376 | 0.89 | MPO (0.51) | MPOTPOKCNH2CYP3A4MEN1 | |
| SCHEMBL27224199 | 0.86 | MPO (0.56) | MPOTPOKCNH2CYP3A4PNP | |
| SCHEMBL27223377 | 0.86 | MPO (0.54) | MPOTPOKCNH2CYP3A4 | |
| SCHEMBL27223609 | 0.86 | MPO (0.56) | MPOTPOKCNH2CYP3A4PNP | |
| SCHEMBL27223956 | 0.81 | MPO (0.57) | MPOTPOKCNH2CYP3A4PNP | |
| SCHEMBL30749262 | 0.81 | MPO (0.50) | MPOTPOKCNH2CYP3A4PNP | |
| SCHEMBL30749245 | 0.76 | MPO (0.54) | MPOTPOKCNH2CYP3A4MEN1 | |
| SCHEMBL30749267 | 0.76 | MPO (0.38) | MPOTPOKCNH2CYP3A4 | |
| SCHEMBL30749208 | 0.76 | MPO (0.51) | MPOTPOKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024038131-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | MPO, XDH, EPX | MPO 1/4885TPO 10/4885KCNH2 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.